Compare ETD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | PHAR |
|---|---|---|
| Founded | 1932 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.5M | 1.1B |
| IPO Year | 1993 | N/A |
| Metric | ETD | PHAR |
|---|---|---|
| Price | $23.58 | $16.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $28.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 301.3K | 22.5K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 7.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.85 | 0.00 |
| Revenue | ★ $607,296,000.00 | $362,274,000.00 |
| Revenue This Year | N/A | $24.80 |
| Revenue Next Year | $3.32 | $6.84 |
| P/E Ratio | ★ $12.75 | $2,946.57 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $21.67 | $7.50 |
| 52 Week High | $32.61 | $18.12 |
| Indicator | ETD | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 51.06 |
| Support Level | $23.83 | $16.23 |
| Resistance Level | $24.46 | $17.00 |
| Average True Range (ATR) | 0.56 | 0.75 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 5.52 | 36.44 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.